INCB-62079

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameINCB-62079
Drug Alias NameINCB-62079INCB-062079
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptors antagonistsFibroblast growth factor receptor 4 antagonists
TargetsFibroblast growth factor receptorsFibroblast growth factor receptor 4
Therapy Area/IndicationsSolid tumoursNasopharyngeal NeoplasmsOvarian Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesIncyte Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIncyte Corp
Active IndicationsN/A
Inactive IndicationsSolid tumoursNasopharyngeal NeoplasmsOvarian Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A